Abstract: The present invention relates to novel (meth)acrylic esters of polyalkoxylated trimethylolpropane of the formula where AO is for each AO independently at each instance EO, PO or BO where EO is O—CH2-CH2- PO is independently at each instance O—CH2-CH(CH3)- or O—CH(CH3)-CH2- BO is independently at each instance O—CH2-CH(CH2-CH3)- or O—CH(CH2-CH3)-CH2- p1+p2+p3 is 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 or 75, R1, R2 and R3 are independently H or CH3, a simplified process for preparing these esters and the use of reaction mixtures thus obtainable.

Abstract: The present invention inter alia relates to methods for the prevention, amelioration or treatment of medical conditions associated with an alteration in normal goblet cell function. It also relates to methods of screening for disease-relevant markers indicative of an increased risk of a subject of developing such a condition. It furthermore relates to an animal model useful for studying said conditions and the molecular mechanisms underlying them, and uses of that animal model, for example for the identification of diagnostic markers or agents useful for the prevention, amelioration, or treatment of a goblet cell-related disorder. Novel agents useful in the above methods, and novel pharmaceutical compositions are likewise provided. The invention further relates to screening methods for agonists and antagonists useful for performing said methods.

Abstract: The present invention relates to novel (meth)acrylic esters of polyalkoxylated glycerol, a simplified process for preparing these esters and the use of reaction mixtures thus obtainable.

Abstract: The present invention inter alia relates to methods for the prevention, amelioration or treatment of medical conditions associated with an alteration in normal goblet cell function. It also relates to methods of screening for disease-relevant markers indicative of an increased risk of a subject of developing such a condition. It furthermore relates to an animal model useful for studying said conditions and the molecular mechanisms underlying them, and uses of that animal model, for example for the identification of diagnostic markers or agents useful for the prevention, amelioration, or treatment of a goblet cell-related disorder. Novel agents useful in the above methods, and novel pharmaceutical compositions are likewise provided. The invention further relates to screening methods for agonists and antagonists useful for performing said methods.

Abstract: Compositions of bacteriorhodopsin variants with increased memory time and their use for reversible optical information recording are disclosed. The compositions are characterized in that the configuration of the retinal of the photoproduct is different from the configuration of the retinal of the initial state and other than 13-cis; the pH value of the composition lies between 3 and 11; the water content of the composition lies between 1 and 30% by weight with respect to the total weight of the composition; and additives for modulating the proton mobility are present in a concentration between 1 and 80% by weight of the mass of purple membrane composition used, and if required matrix materials in a concentration of up to 10% by weight with respect to the total weight of the composition are present. These compositions may be used in reversible information recording systems.

Abstract: Purple membrane preparations having an increased holographic diffraction efficiency. The purple membrane preparations have a diffraction efficiency of less than 5 seconds and a resolution of greater than 1,500 lines/mm. The purple membrane preparations are obtainable by adjusting a purple membrane suspension having a photocycle time of at least 10 ms to a pH of between 6 and 11 by means of a buffer, adding from 1% to 10% by weight of a proton donor to this purple membrane suspension, and drying the resultant suspension down to a water content of from 1% to 30% by weight.